Venus Remedies share news, announcements and annual reports
NSE: VENUSREMBSE: 526953Pharmaceuticals & BiotechnologySmall Cap
Venus Remedies Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 1995 on BSE, Dec 2006 on NSE
Last close ₹1,238.60down ₹50.70 (3.93%)BSE ₹1,231.75
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,289.30.
30 Oct: open ₹1,290.00, high ₹1,319.00, low ₹1,225.10
52-week range of traded prices to 30 Oct 2026
₹432.10Low, 31 Oct 2025₹2,044.30High, 29 Jun 2026
- Under NSE's long-term additional surveillance, stage IV, on the list for 30 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,656 Cr1,337th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 13.61
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.35
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.81%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 18.7%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 21.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 48,127
Venus Remedies share news and announcements
697 announcements, routine notices left out, newest first. Page 10 of 14.
Jun 2015
May 2015
15 May · Code of Conduct under SEBI(PIT) Reg., 2015
Feb 2015
4 Feb · Board meeting
To inter alia consider and approve Unaudited Financial Results (Provisional) for the quarter ended 31.12.2014.
Jan 2015
29 Jan · Corporate Debt Restructuring
Corporate Debt Restructuring Cell (CDR Cell) has approved the CDR proposal of the Company. In accordance with the same, inter alia, the moratorium period of the repayments of the principal borrowings has been extended to two years w.e.f. April 1, 2014. The lenders have also sanctioned financial assistance towards repayment commitments of FCCBs of the Company, due in February, 2015. With this, the company has concluded its financial restructuring. The implementation process of the CDR is underway.
Dec 2014
Nov 2014
28 Nov · Meeting
Register of Members & Share Transfer Books shall remain closed from December 23, 2014 to December 30, 2014 (both days inclusive) for the purpose of the Annual General Meeting proposed to be held on December 30, 2014.15 Nov · Board meeting
Board of Directors of the Company at its meeting held on November 14, 2014, inter alia, has approved the following: 1. Approved to withdraw the recommendation of dividend for the year 2013-14 in the light of lending institutions terms of Corporate Debt Rephasing which have mandated not to declare dividend for the year 2013-14. In compliance of such terms, the recommendation of the dividend made on August 13, 2014 stands withdrawn by the Board. Consequently the Board approved the revision of Audited Financial Results for the year ended on March 31, 2014 to the extent of removal of accounting for dividend @ 30% for the year March 31, 2014. There is no other revision of the audited balance sheet.7 Nov · Board meeting
To inter alia consider and approve following items: 1. Unaudited Financial Results for the quarter ended September 30, 2014. 2. To fix date of Annual General Meeting. 3. To consider any other business with the permission of the Chair.
Sep 2014
17 Sep · Meeting
Registrar of Companies has granted extension of three months for holding the Annual General Meeting pertaining to financial year ended at March 31, 2014 in the light of the ongoing preparations by the Company for providing the e-voting platform to the shareholders. Now, the Annual General Meeting will be held after September 30, 2014 latest by December 31, 2014 once the e-voting platform is ready.16 Sep · Rating
Aug 2014
13 Aug · Results
6 Aug · Board meeting
To inter alia consider and approve Unaudited Financial Results of the Company for the Quarter ended June 30, 2014 and to consider other business with the permission of the Chair.
Jun 2014
3 Jun · Dividend
Board of Directors of the Company at its meeting held on May 30, 2014 has recommended a dividend @ 30% i.e. Rs 3/- per share for the financial year ended March 31, 2014 subject to approval of the same by shareholders at the Annual General Meeting.
May 2014
21 May · Board meeting
To inter alia consider and approve Audited Financial Results for the quarter ended 31.03.2014, Audited Financial Results for the financial year 2013-2014 and any other item with the permission of chair.21 May · Legal
Exchange had sought clarification from Venus Remedies Limited with respect to news item captioned "Venus ties up with Lupin to sell antibiotic drug in Oz.". The Company has clarified that "The Company is already exporting the product Meropenem to 35 countries. This product is a generic product and one of our 75 product basket and after this market authorization approval, company plans to market the drug by the third quarter of this year in Australia and company has tied up with Lupin to sell this drug in Australia. This news/article is important as a showcase of our achievement. However, this has a moderate economic impact on our organization because our business prospects from sale of Meropenem in Australia market would be less than 1% of total revenue. Meropenem is an off-patented antibacterial agent of the carbapenem class of antibiotics that caters to diseases with a broad range of serious infections caused by single or multiple susceptible bacteria in both adults and children".
Apr 2014
Feb 2014
12 Feb · Results
3 Feb · Board meeting
To inter alia consider and approve Unaudited Financial Results for the quarter ended December 31, 2013.
Jan 2014
Dec 2013
Nov 2013
18 Nov · Results
5 Nov · Board meeting
To inter alia consider and approve Unaudited Financial Results for the quarter ended September 30, 2013.
Oct 2013
Sep 2013
Aug 2013